It would seem that the time when machines surpass the ability of humans to do intricate work is almost here. One of Google’s Artificial Intelligence projects is apparently capable of diagnosing the retina of patients to see if they are about to go blind. The search engine company even went so far as to claim that the AI is better than actual doctors at diagnosis.
As Google noted in a blog post about the AI, Diabetic retinopathy is a quickly rising cause of blindness among patients in the world. The disease is treatable, but only if it is caught early enough to respond to treatments. This is where effective diagnosis comes into play.
“Unfortunately, medical specialists capable of detecting the disease are not available in many parts of the world where diabetes is prevalent,” the blog post reads. “We believe that Machine Learning can help doctors identify patients in need, particularly among underserved populations.”
The findings with regards to the diagnostic capabilities of the AI was published in the Journal of the American Medical Association. The paper included proposals on certain potential benefits that machine learning could provide with regards to diagnosing medical problems and even helping to find ways to treat them.
In the case of blindness caused by Diabetic retinopathy, the AI is fed images of retinas, which it will then scan and analyze for any of the telltale sign of impending blindness. After going through 128,000 images of retinas with the traits that led to the condition, the AI was given 10,000 new images to diagnose. Based on the results, the machine was much better at detecting which images posed the biggest threat of blindness for the subjects.
There are significant advantages to having this kind of powerful tool, especially with regards to detecting and curing diseases. However, there is also the startling implication that if a machine can replace vocations as complex and important as those in the medical profession, just how much of human society can AI replace?


Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence
Rewardy Wallet and 1inch Collaborate to Simplify Multi-Chain DeFi Swaps with Native Token Gas Payments
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 



